Published: 23 November 2022

Authors: Walter Ageno, Lorenza Bertù, Eugenio Bucherini, Giuseppe Camporese, Francesco Dentali, Matteo Lotti, Gianfranco Lessiani, Roberto Parisi, Paolo Prandoni, Michelangelo Sartori, Adriana Visonà, Elisabetta Bigagli, Gualtiero Palareti, on behalf of the RIDTS study group

Source: This abstract has been sourced from NZ Respiratory Research Review Issue 207


    Objective To compare two different treatment durations of rivaroxaban in patients with symptomatic isolated distal deep vein thrombosis (DVT).

    Design Randomised, double blind, placebo controlled clinical trial.

    Setting 28 outpatient clinics specialising in venous thromboembolism.

    Participants 402 adults (≥18 years) with symptomatic isolated distal DVT.

    Interventions After receiving standard dose rivaroxaban for six weeks, participants were randomly assigned to receive rivaroxaban 20 mg or placebo once daily for an additional six weeks. Follow-up was for 24 months from study inclusion.

    Main outcomes measures The primary efficacy outcome was recurrent venous thromboembolism during follow-up after randomisation, defined as the composite of progression of isolated distal DVT, recurrent isolated distal DVT, proximal DVT, symptomatic pulmonary embolism, or fatal pulmonary embolism. The primary safety outcome was major bleeding after randomisation until two days from the last dose of rivaroxaban or placebo. An independent committee adjudicated the outcomes.

    Results 200 adults were randomised to receive additional rivaroxaban treatment and 202 to receive placebo. Isolated distal DVT was unprovoked in 81 (40%) and 86 (43%) patients, respectively. The primary efficacy outcome occurred in 23 (11%) patients in the rivaroxaban arm and 39 (19%) in the placebo arm (relative risk 0.59, 95% confidence interval 0.36 to 0.95; P=0.03, number needed to treat 13, 95% confidence interval 7 to 126). Recurrent isolated distal DVT occurred in 16 (8%) patients in the rivaroxaban arm and 31 (15%) in the placebo arm (P=0.02). Proximal DVT or pulmonary embolism occurred in seven (3%) patients in the rivaroxaban arm and eight (4%) in the placebo arm (P=0.80). No major bleeding events occurred.

    Conclusions Rivaroxaban administered for six additional weeks in patients with isolated distal DVT who had an uneventful six week treatment course reduces the risk of recurrent venous thromboembolism, mainly recurrent isolated distal DVT, over a two year follow-up without increasing the risk of haemorrhage.

    Trial registration EudraCT 2016-000958-36; NCT02722447.

    Link to abstract

    Have you read

    View all